This trial is testing a new treatment for multiple myeloma that may help patients achieve remission.
- Multiple Myeloma
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
94 Total Participants · 2 Treatment Groups
Primary Treatment: Belantamab mafodotin · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Mohan, Meera, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Sunilkumar Kakadia, Manojna Konda, Anusha Jillella, et al.. 2022. “Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease After First Transplantation in Multiple Myeloma”. American Journal of Hematology. Wiley. doi:10.1002/ajh.26530.
- Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. No abstract available.
- 2022. "Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05091372.
Frequently Asked Questions
What potential hazards are associated with Belantamab mafodotin?
"Taking into account the lack of evidence regarding efficacy, Belantamab mafodotin was assigned a safety score of 2." - Anonymous Online Contributor
What is the current participant count for this experiment?
"As of October 29th 2021, this trial is no longer enrolling patients. It was first posted on April 30th 2022 and has not been edited since then. Fortunately, 859 trials are available for those seeking treatment for multiple myeloma and a further 293 studies require participants taking Belantamab mafodotin." - Anonymous Online Contributor
What maladies is Belantamab mafodotin typically employed to treat?
"Belantamab mafodotin is widely used to combat chronic lymphocytic leukemia, but may also be deployed for those with amyloidosis or relapsed/refractory multiple myeloma who have received at least two prior systemic chemotherapy regimens." - Anonymous Online Contributor
Is enrollment still open for this clinical investigation?
"On clinicaltrials.gov, this medical experiment is not currently enrolling patients; the trial was first posted to the website on April 30th 2022 and lately updated October 29th 2021. Nonetheless, 1152 other studies are actively searching for participants presently." - Anonymous Online Contributor